Carl Zeiss Meditec AG | Deep-Dive: ZEISS SMILE | Thu Anh Klimpke, Investor Relations

We’re thrilled to announce that Thu Anh Klimpke, Investor Relations of ZEISS Medical Technology Segment, is presenting a Deep Dive on the revolutionary Zeiss Smile procedure and exploring the future of laser vision correction. Topics related to the company's strategic business units, including the myopia trend, refractive laser surgery with ZEISS Smile, and more will also be covered. During her presentation, Thu Anh provides valuable insights into the ZEISS Medical Technology Segment's structure and offerings, which include two strategic business units: Ophthalmology and Microsurgery. Within the Ophthalmology unit, ZEISS focuses on three key areas: ophthalmic diagnostics, surgical ophthalmology, and refractive laser surgery. Thu Anh will delve into each area, closely examining the devices and consumables ZEISS offers. A key topic will be the myopia trend. According to a study, one-third of the world's population currently has myopia, with high myopia affecting one in 20 people. Thu Anh will explore the development of myopia in the coming decades, highlighting the increasing importance of laser vision correction for more individuals. Moreover, Thu Anh will discuss ZEISS's Smile technology, which stands for Small Incision Lenticule Extraction. She will explain how this technology differs from conventional laser vision correction procedures and how ZEISS provides a standalone solution. Thu Anh will also provide a detailed overview of the Visa Max 800, a femtosecond system known for its outstanding incision precision, speed, and gentle treatment approach. Attendees will gain valuable insights into the ZEISS Medical Technology Segment's offerings and learn how the company is leading the way in laser vision correction technology. Don't miss this opportunity to learn from Thu Anh, Manager of Investor Relations for the ZEISS Medical Technology Segment. Other videos: ⁠Elevator Pitch⁠ ⁠Company Presentation⁠ ⁠Deep Dive Presentation⁠ ⁠Financial Results Presentation⁠ ⁠ESG Presentation⁠ T&C: This publication is for informational purposes only and does not constitute investment advice. By using this website, you agree to our terms and conditions outlined on ⁠www.seat11a.com/legal⁠ and ⁠www.seat11a.com/imprint⁠.